BaseLaunch is top European accelerator
Healthcare Accelerator BaseLaunch, which is operated by the location promotion organization BaselArea.swiss, is among the leading accelerators of its kind in Europe, according to a media report. BaseLaunch is the only Swiss Healthcare Accelerator to feature.
“Sifted”, an online magazine supported by the “Financial Times”, has analyzed the leading Healthcare Accelerators in Europe. It aimed to find out which accelerators provide healthcare startups with the best opportunities for development and to find investment.
The list of the best European accelerators that specialize in healthcare is very short, with “Sifted” naming just eleven institutions. BaseLaunch, which is operated by BaselArea.swiss, is the only Swiss institution to feature. According to the article, BaseLaunch is the rarest type of accelerator – it provides investment and support without asking for equity in return. Instead, big industry funding comes from companies like Novartis, Roche, Roivant Sciences, Johnson & Johnson, Pfizer and KPMG.
Basel is already world-famous in life sciences, but BaseLaunch is supporting even more startups making exciting developments. It offers them business development and legal services, as well as fully equipped labs. Furthermore, grants are available up to 250,000 Swiss francs per company by the end of the 15-month programme. BaseLaunch looks for companies innovating in the therapeutics space, medtech and diagnostics.
In Germany, the only country in which “Sifted” names several high-ranking healthcare accelerators, there are three institutions listed. Like Switzerland, the other countries featured – Great Britain, Sweden, the Netherlands, Spain, Italy, Denmark and Hungary – have only one accelerator included in the ranking.
Share this article
You might also be interested in
The Japanese conglomerate Yokogawa has established a Swiss subsidiary based at the Switzerland Innovation Park Basel Area. Here, the focus will be on driving forward innovation in the field of biotechnology.Read More
The Werner Siemens Foundation is to invest an additional 12 million Swiss francs in the Miracle project. Researchers at the University of Basel are developing visionary technology for the use of robots in surgery within the framework of this project.Read More
The Basel-based biopharmaceutical company Versameb has successfully closed a seed financing round. Versameb develops therapies on the basis of mRNA sequences and is now seeking to drive forward the clinical development of its platform devised for this.Read More
Two thirds of the value added attributable to the pharmaceutical industry as a whole in Switzerland is generated in the Basel Area, as revealed by an Interpharma report. However, the region also shines in an international comparison. Interpharma CEO René Buholzer regards it as “probably the most productive life sciences location in the world”.Read More
Resistell AG, based in Muttenz in the canton of Basel-Landschaft, has received a grant of up to 2.5 million euros and additional equity capital financing from a European fund with the aim of accelerating innovation. The company is developing the world’s fastest test against antibiotic resistance.Read More
We are happy to present our latest addition to the Switzerland Innovation Park Basel Area: Our site on the Novartis Campus dedicated to digital health provides a focal point to a unique community of digital healthcare experts.Read More